Chlamydia trachomatis isolates are differentiated serologically into three serogroups with a total of 15 distinct serovars: the B serogroup (serovars B, Ba, D, E, Li, and L2), the intermediate serogroup (serovars F, G, K, and L3), and the C serogroup (serovars A, C, H, I, and J) (5, 12, 13) . Serovars A, B, Ba, and C are the etiological agents of trachoma, the world's leading cause of preventable blindness (4) . Serovars D through K are sexually transmitted pathogens that cause chlamydial urethritis, epididymitis, cervicitis, and pelvic inflammatory disease (PID).
Trachoma and PID are the most significant chlamydial diseases in terms of both severity and the number of persons afflicted. Trachoma is the leading cause of preventable blindness in the world; an estimated 500 million people in developing nations suffer from this disease (4) . Chlamydial PID causes severe scarring of the fallopian tubes, which leads to tubal obstruction and may result in tubal blockage or ectopic pregnancy. It is estimated that chlamydial PID afflicts 400,000 women per annum in the United States (14) .
Immunoprophylaxis has been suggested as a possible means for the control or prevention of blinding trachoma (6, 10) and may be a plausible approach for the control of sexually transmitted chlamydial infections. Protective immunity to chlamydial ocular infection is homotypic (6, 8) , suggesting that serovar-specific antigenic determinants may be useful as candidates for the development of a chlamydial vaccine. Immunization with serovar-specific antigen(s) is a feasible approach for the development of a trachoma vaccine, since few serovars cause infection; however, it would not be a credible strategy in the case of sexually transmitted diseases because of the greater number of C. trachomatis serovars associated with these infections.
The major outer membrane protein (MOMP) is the primary chlamydial serotyping antigen; this molecule contains antigenic determinants which elicit serovar-, subspecies-, serogroup-, and species-specific antibodies (3, 9, 11). Monoclonal antibodies (MAbs) that recognize B serovar-specific and B complex-specific epitopes of the MOMP passively neutralize both chlamydial toxicity for mice and chlamydial infectivity for monkey conjunctivae (15 Chlamydiae were grown in HeLa 229 cells, and elementary bodies (EBs) were purified by centrifugation on Renografin density gradients (2, 7) . The procedures for immunization, generation of murine hybridomas, and screening of hybridoma supernatants for the presence of chlamydial antibodies have been described previously (15) . Briefly, hybridoma supernatants were screened by the dot immunoblot assay with viable EBs as antigen. Positive supernatants were then screened by Western blot (immunoblot) to verify their binding to the MOMP. MAbs showing immunoreactivity in both assays were selected, since they most likely recognize contiguous MOMP determinants that were both immunogenic and antigenic on the native chlamydial cell surface. We sought contiguous protective determinants since our future objective is to express these determinants as fusion proteins at the cell surface of infectious enteric bacterial and viral vectors-vaccine-based vectors that require a minimal amount of inserted foreign sequence.
The MAbs were assayed for their ability to neutralize chlamydial toxicity for mice. The assay was done as previously described (15 The ability of these MAbs to neutralize chlamydial toxicity in mice is shown in Table 1 . Both serovar-specific and serogroup-specific MAbs passively protected mice from toxic death. The ability of antibody to neutralize toxicity correlated with the surface accessibility of its MOMP epitope. For example, MAb L21-5 reacted poorly with serovar B by dot immunoblot assay and did not protect mice from toxic death. However, this antibody reacted strongly with the cell surface of serovar D EBs and neutralized the toxicity of this serovar for mice. MAb L2I-6, which reacts with a surface-accessible, genus-specific epitope located on chlamydial lipopolysaccharide (1), does not protect mice, indicating that binding of antibody to the cell surface in itself is insufficient to promote neutralization. These findings support a functional role for MOMP in the pathogenesis of chlamydial toxicity in vivo.
We have identified MAbs specific to trachoma serovars (A, B, Ba, and C) and MAbs that recognize serogroupspecific epitopes. Epitopes recognized by these MAbs were located on the MOMP and were highly accessible to antibody at the chlamydial cell surface. MAbs specific to these MOMP epitopes were protective in the mouse toxicity test. The ability of these MAbs to passively protect against chlamydial infection was not tested. However, in a previous study (15) we observed that MAb B-B6 was protective in the mouse toxicity test and neutralized the infectivity of serovar B for the monkey conjunctivae, suggesting a functional relation between antibody-mediated protection of mouse toxicity and chlamydial infectivity.
We believe that the MAbs described here will be useful reagents for epitope mapping and for defining the molecular structure of these MOMP determinants, a critical step in evaluating their potential as antigens in the development of a synthetic or recombinant chlamydial vaccine.
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